Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement

Obesity Facts

Mireille J. Serlie¹  Dennis T. Villareal²  Hanping Shi³  Maria Cristina Gonzalez⁴  Gema Frühbeck⁵  Maria D. Ballesteros-Pomar⁶  Rocco Barazzoni⁷  Dorothee Volkert⁸  Cornel C. Sieber⁸  Takashi Higashiguchi⁹  Yves Rolland^1,10  Alfonso J. Cruz-Jentoft^1,11  Laurence Genton^1,12  Ibolya Nyulasi^1,13  Jianchun Yu^1,14  Steven B. Heymsfield^1,15  Dror Dicker^1,16  Stefano Frara^1,17  Andrea Giustina^1,17  Alessandro Laviano^1,18  Andrea Lenzi^1,18  Edda Parrinello^1,18  Eleonora Poggiogalle^1,18  Lorenzo M. Donini^1,18  Ho-Seong Han^1,19  Yftach Gepner^2,20  Javier Salvador^2,21  Carla M. Prado^2,22  Yves Boirie^2,23  Juergen M. Bauer^2,24  Stephan C. Bischoff^2,25  John A. Batsis^2,26  Mario Siervo^2,27  Luca Busetto^2,28  Roberto Vettor^2,28  Ferruccio Santini^2,29  Mauro Zamboni^3,30  Tommy Cederholm^3,31 

[1] Amsterdam University Medical Centers, Amsterdam, The Netherlands;Baylor College of Medicine, Houston, TX, USA;Beijing Shijitan Hospital, Capital Medical University, Beijing, China;Catholic University of Pelotas (UCPEL), Pelotas, Brazil;Clínica Universidad de Navarra, CIBEROBN, IdiSNA, Pamplona, Spain;Complejo Asistencial Universitario de León, Altos de Nava, León, Spain;Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy;Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany;Fujita Health University School of Medicine, Aichi, Japan;Gerontopole of Toulouse, INSERM 1027, Toulouse University Hospital, Toulouse, France;Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain;Hôpitaux Universitaires de Genève, Genève, Switzerland;Monash University, Clayton, VIC, Australia;Peking Union Medical College Hospital, Beijing, China;Pennington Biomedical Research Center, Baton Rouge, LA, USA;Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel;San Raffaele, Vita-Salute University and IRCCS Hospital, Milan, Italy;Sapienza University, Rome, Italy;Seoul National University Bundang Hospital (SNUBH), Seoul, Republic of Korea;Tel-Aviv University, Tel-Aviv, Israel;Universidad de Navarra, CIBEROBN, IdiSNA, Pamplona, Spain;University of Alberta, Edmonton, AB, Canada;University of Clermont Auvergne, INRA, CRNH, CHU Clermont-Ferrand, Clermont-Ferrand, France;University of Heidelberg, Heidelberg, Germany;University of Hohenheim, Stuttgart, Germany;University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;University of Nottingham, Nottingham, United Kingdom;University of Padua, Padua, Italy;University of Pisa, Pisa, Italy;University of Verona, Verona, Italy;Uppsala University, Uppsala, Sweden;

关键词: obesity;    sarcopenia;    sarcopenic obesity;   

DOI  :  10.1159/000521241

来源: DOAJ

【 摘 要 】

Introduction: Loss of skeletal muscle mass and function (sarcopenia) is common in individuals with obesity due to metabolic changes associated with a sedentary lifestyle, adipose tissue derangements, comorbidities (acute and chronic diseases) and during the ageing process. Co-existence of excess adiposity and low muscle mass/function is referred to as sarcopenic obesity (SO), a condition increasingly recognized for its clinical and functional features that negatively influence important patient-centred outcomes. Effective prevention and treatment strategies for SO are urgently needed, but efforts are hampered by the lack of a universally established SO definition and diagnostic criteria. Resulting inconsistencies in the literature also negatively affect the ability to define prevalence as well as clinical relevance of SO for negative health outcomes. Aims and Methods: The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) launched an initiative to reach expert consensus on a definition and diagnostic criteria for SO. The jointly appointed international expert panel proposes that SO is defined as the co-existence of excess adiposity and low muscle mass/function. The diagnosis of SO should be considered in at-risk individuals who screen positive for a co-occurring elevated body mass index or waist circumference, and markers of low skeletal muscle mass and function (risk factors, clinical symptoms, or validated questionnaires). Diagnostic procedures should initially include assessment of skeletal muscle function, followed by assessment of body composition where presence of excess adiposity and low skeletal muscle mass or related body compartments confirm the diagnosis of SO. Individuals with SO should be further stratified into stage I in the absence of clinical complications or stage II if cases are associated with complications linked to altered body composition or skeletal muscle dysfunction. Conclusions: ESPEN and EASO, as well as the expert international panel, advocate that the proposed SO definition and diagnostic criteria be implemented into routine clinical practice. The panel also encourages prospective studies in addition to secondary analysis of existing data sets, to study the predictive value, treatment efficacy and clinical impact of this SO definition.

【 授权许可】

Unknown